<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03995888</url>
  </required_header>
  <id_info>
    <org_study_id>BED-PSMA-101</org_study_id>
    <nct_id>NCT03995888</nct_id>
  </id_info>
  <brief_title>Assessing Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA-7.3) (18F) in Healthy Volunteers and Subjects With Prostate Cancer</brief_title>
  <official_title>A Phase 1, Open-label Study to Assess Safety, Biodistribution, and Internal Radiation Dosimetry of rhPSMA-7.3 (18F) Injection in Healthy Volunteers, and to Assess Safety and Investigate the Imaging Characteristics in Subjects With Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Blue Earth Diagnostics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Blue Earth Diagnostics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1, Open-label Study to Assess Safety, Biodistribution, and Internal Radiation
      Dosimetry of rhPSMA-7.3 (18F) Injection in Healthy Volunteers, and to Assess Safety and
      Investigate the Imaging Characteristics in Subjects With Prostate Cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 11, 2019</start_date>
  <completion_date type="Actual">April 16, 2020</completion_date>
  <primary_completion_date type="Actual">April 16, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Positron Emission Tomography (PET) Imaging study</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as classified by MedDRA</measure>
    <time_frame>1 month</time_frame>
    <description>Safety will be assessed from data on the occurrence of one or more treatment-emergent Adverse Events from the time of intravenous administration of 18F-rhPSMA-7.3 throughout the study period, and changes in serum biochemistry, hematology, coagulation, urinalysis, vital signs, Electrocardiogram (ECG), injection site status, and physical examination findings.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dosimetry estimates</measure>
    <time_frame>24 hours</time_frame>
    <description>Dosimetry estimates in megagray/MegaBecquerel (mGy/MBq) by source region, including analysis of radioactivity in whole blood, plasma and excreted urine in healthy volunteers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulated activity exposure</measure>
    <time_frame>24 hours</time_frame>
    <description>Whole body radioactivity dose in MilliSievert/MegaBecquerel (mSv/MBq).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uptake of rhPSMA-7.3 18F</measure>
    <time_frame>24 hours</time_frame>
    <description>Uptake of 18F-rhPSMA-7.3 injection visualized by PET imaging compared to histopathology in subjects with Prostate Cancer, where histopathology information is available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of 18F-rhPSMA-7.3</measure>
    <time_frame>24 hours</time_frame>
    <description>Use of kinetic modelling data to investigate distribution of 18F-rhPSMA7.3 in subjects with Prostate Cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In vivo 18F radioactivity in Prostate Cancer lesions</measure>
    <time_frame>24 hours</time_frame>
    <description>Use of kinetic modelling data to optimize the imaging protocol for future studies in subjects with Prostate Cancer, by estimating in vivo 18F radioactivity in Prostate Cancer lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% of radioactive parent compound present in plasma</measure>
    <time_frame>24 hours</time_frame>
    <description>Analysis of % of radioactive parent compound present in plasma over time in healthy volunteers and subjects with Prostate Cancer. Relative proportions of radioactive tracer metabolites will be monitored if detected in significant amounts in the radio-High Performance Liquid Chromatography (HPLC) analysis.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous administration of rhPSMA-7.3 (18F) for PET Scan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous administration of rhPSMA-7.3 (18F) for PET Scan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhPSMA-7.3 (18F) Injection</intervention_name>
    <description>Radioligand for PET CT scanning</description>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria: Healthy Volunteers

          1. Male and females 21-65 years.

          2. Clinically acceptable medical history

        Key Exclusion Criteria: Healthy Volunteers

          1. Received ionising radiation exposure from clinical trials or medical examinations or
             treatment in the last 12 months.

          2. Suffers from claustrophobia.

          3. Bilateral hip prostheses.

        Key Inclusion Criteria: Patients

          1. Male 18-80 years.

          2. Histologically confirmed adenocarcinoma of the prostate

          3. Clinically acceptable medical history

          4. Eastern Cooperative Oncology Group (ECOG) performance status 0-2

        Key Exclusion Criteria: Patients

          1. Biopsy 28 days prior to enrollment.

          2. Extensive metastatic disease.

          3. Underlying disease which might confound interpretation.

          4. Bilateral hip prostheses.

          5. High energy (&gt;300 Kiloelectron Volt (keV)) gamma-emitting radioisotope administered
             within five physical half-lives, or any intravenous iodinated contrast medium within
             24 hours, or any high density oral contrast medium (oral water contrast is acceptable)
             within 5 days prior to study drug administration.

          6. X-ray contrast agent (&lt;24 hr for intravenous agents and &lt;5 days for oral agents).

          7. History of claustrophobia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mika Scheinin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Research Services Turku - CRST Oy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Services Turku - CRST Oy</name>
      <address>
        <city>Turku</city>
        <zip>FI-20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 18, 2019</study_first_submitted>
  <study_first_submitted_qc>June 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2019</study_first_posted>
  <last_update_submitted>May 15, 2020</last_update_submitted>
  <last_update_submitted_qc>May 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

